Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin

Although survival in pediatric acute myeloid leukemia (AML) has increased considerably over the past decades, refractory disease and relapse rates remain high. Refractory and relapsed disease are difficult to treat, with overall survival rates less than 40–50%. Preventing relapse should, therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijnen, Noa E, Koedijk, Joost B, Klein, Kim, Luesink, Maaike, Goemans, Bianca F, Zwaan, C Michel, Kaspers, Gertjan J L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155714/
https://www.ncbi.nlm.nih.gov/pubmed/37153641
http://dx.doi.org/10.2147/OTT.S263829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155714/
https://www.ncbi.nlm.nih.gov/pubmed/37153641
http://dx.doi.org/10.2147/OTT.S263829

Ejemplares similares